{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:16:58Z","timestamp":1765887418233,"version":"3.44.0"},"reference-count":154,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1053\/j.seminhematol.2012.05.003","type":"journal-article","created":{"date-parts":[[2012,6,20]],"date-time":"2012-06-20T17:39:13Z","timestamp":1340213953000},"page":"S16-S32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"S1","title":["Management Strategies for Relapsed\/Refractory Multiple Myeloma: Current Clinical Perspectives"],"prefix":"10.1053","volume":"49","author":[{"given":"Andrzej","family":"Jakubowiak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2012.05.003_bib1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/ajh.2830330203","article-title":"VAD-based regimens as primary treatment for multiple myeloma","volume":"33","author":"Alexanian","year":"1990","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V31.1.1.1","article-title":"Melphalan therapy for plasma cell myeloma","volume":"31","author":"Alexanian","year":"1968","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib3","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood.V80.4.887.887","article-title":"Primary dexamethasone treatment of multiple myeloma","volume":"80","author":"Alexanian","year":"1992","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1053\/j.seminhematol.2012.05.003_bib4","first-page":"118","article-title":"Myeloablative therapy for primary resistant multiple myeloma","volume":"13","author":"Alexanian","year":"1995","journal-title":"Stem Cells"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib6","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4065\/79.7.867","article-title":"Clinical course of patients with relapsed multiple myeloma","volume":"79","author":"Kumar","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0609.2010.01542.x","article-title":"Emerging therapies for the treatment of relapsed or refractory multiple myeloma","volume":"86","author":"Dimopoulos","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib8","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00277-009-0856-x","article-title":"Korean Multiple Myeloma Working Party (KMMWP)","volume":"89","author":"Kim","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib9","doi-asserted-by":"crossref","first-page":"5676","DOI":"10.1200\/JCO.2009.24.3683","article-title":"Relapse\/refractory myeloma patient: potential treatment guidelines","volume":"27","author":"San Miguel","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/leu.2011.310","article-title":"Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and \u2018retreatment\u2019 approaches in the era of novel agents","volume":"26","author":"Mohty","year":"2012","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib11","unstructured":"National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology. Multiple myeloma. Version 1.2012."},{"issue":"Suppl 5","key":"10.1053\/j.seminhematol.2012.05.003_bib12","doi-asserted-by":"crossref","first-page":"v155","DOI":"10.1093\/annonc\/mdq178","article-title":"Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Harousseau","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib13","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood.V70.3.869.869","article-title":"High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma","volume":"70","author":"Barlogie","year":"1987","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib14","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1182\/blood.V67.5.1298.1298","article-title":"High-dose melphalan with autologous bone marrow transplantation for multiple myeloma","volume":"67","author":"Barlogie","year":"1986","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.7326\/0003-4819-105-1-8","article-title":"High-dose glucocorticoid treatment of resistant myeloma","volume":"105","author":"Alexanian","year":"1986","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib16","first-page":"2115","article-title":"A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma","volume":"9","author":"Gertz","year":"1995","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib17","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJM198405243102104","article-title":"Effective treatment of advanced multiple myeloma refractory to alkylating agents","volume":"310","author":"Barlogie","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib18","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/00000421-199512000-00003","article-title":"Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma","volume":"18","author":"Gertz","year":"1995","journal-title":"Am J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2141.1989.tb06269.x","article-title":"VAD chemotherapy for refractory multiple myeloma","volume":"71","author":"Lokhorst","year":"1989","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib20","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3109\/10428199509056859","article-title":"A randomized study of MOD versus VAD in the treatment of relapsed and resistant multiple myeloma","volume":"17","author":"Phillips","year":"1995","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib21","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.1986.4.8.1227","article-title":"Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group study","volume":"4","author":"Durie","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib22","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/(SICI)1096-8652(200003)63:3<125::AID-AJH3>3.0.CO;2-S","article-title":"Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: an International Oncology Study Group (IOSG) phase II protocol","volume":"63","author":"Giles","year":"2000","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib23","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/bjc.1995.65","article-title":"VAD chemotherapy as remission induction for multiple myeloma","volume":"71","author":"Anderson","year":"1995","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib24","first-page":"41","article-title":"Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients","volume":"12","author":"Dadacaridou","year":"2007","journal-title":"J Buon"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib25","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1200\/JCO.2003.01.055","article-title":"DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma","volume":"21","author":"Lee","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib26","article-title":"Dexamethasone, cyclophosphamide, etoposide and cisplatinum (DCEP), an effective regimen for relapse after high-dose chemotherapy and autologous transplantation (AT)","volume":"88","author":"Munshi","year":"1996","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib27","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2005-09-3869","article-title":"Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma","volume":"107","author":"Garban","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib28","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.1995.13.6.1312","article-title":"Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma","volume":"13","author":"Gahrton","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib29","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.bbmt.2004.06.002","article-title":"Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan\/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma","volume":"10","author":"Kr\u00f6ger","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib30","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1080\/10428190903085936","article-title":"Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma","volume":"50","author":"Burzynski","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib31","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/ajh.20641","article-title":"Prolonged overall survival with second on-demand autologous transplant in multiple myeloma","volume":"81","author":"Elice","year":"2006","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib32","first-page":"275","article-title":"Second autologous transplantation for multiple myeloma patients relapsing after the first autograft\u2014a pilot study for the evaluation of experimental maintenance therapies. Report of the prospective non-randomized pilot study of the","volume":"27","author":"Krivanov\u00e1","year":"2004","journal-title":"Onkologie"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib33","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/bmt.2008.334","article-title":"Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma","volume":"43","author":"Olin","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib34","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/cncr.21700","article-title":"Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma","volume":"106","author":"Qazilbash","year":"2006","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib35","first-page":"141","article-title":"The role of second autografts in the management of myeloma at first relapse","volume":"91","author":"Alvares","year":"2006","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib36","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib37","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.V98.2.492","article-title":"Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients","volume":"98","author":"Barlogie","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib38","first-page":"408","article-title":"Salvage therapy with thalidomide in patients with advanced relapsed\/refractory multiple myeloma","volume":"87","author":"Tosi","year":"2002","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib39","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/sj.thj.6200175","article-title":"Thalidomide in patients with advanced multiple myeloma: a study of 83 patients\u2014report of the Intergroupe Fran\u00e7ophone du Myelome (IFM)","volume":"3","author":"Yakoub-Agha","year":"2002","journal-title":"Hematol J"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib40","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1046\/j.1365-2141.2000.01983.x","article-title":"Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma","volume":"109","author":"Juliusson","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib41","doi-asserted-by":"crossref","first-page":"875","DOI":"10.4065\/79.7.875","article-title":"Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity","volume":"79","author":"Richardson","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib42","first-page":"404","article-title":"Thalidomide treatment of resistant or relapsed multiple myeloma patients","volume":"86","author":"Hus","year":"2001","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib43","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/sj.leu.2403568","article-title":"Analysis of efficacy and toxicity of thalidomide in 122 patients with multiple myeloma: response of soft-tissue plasmacytomas","volume":"19","author":"Wu","year":"2005","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib44","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1182\/blood-2002-09-2846","article-title":"Multicenter phase 2 trial of thalidomide in relapsed\/refractory multiple myeloma: adverse prognostic impact of advanced age","volume":"102","author":"Mileshkin","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib45","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2141.2004.04879.x","article-title":"Early response predicts thalidomide efficiency in patients with advanced multiple myeloma","volume":"125","author":"Waage","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib46","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/j.1365-2141.2005.05914.x","article-title":"A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma","volume":"132","author":"Glasmacher","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib47","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1600-0609.2011.01729.x","article-title":"Low-dose v. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myelome","volume":"88","author":"Yakoub-Agha","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib48","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3324\/haematol.2011.044271","article-title":"Thalidomide versus dexamethasone for the treatment of relapsed and\/or refractory multiple myeloma: results from OPTIMUM, a randomized trial","volume":"97","author":"Kropff","year":"2012","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib49","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/sj.leu.2403322","article-title":"The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed\/refractory multiple myeloma","volume":"18","author":"Garc\u00eda-Sanz","year":"2004","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib50","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1365-2141.2005.05521.x","article-title":"Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma","volume":"129","author":"Kyriakou","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib51","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1080\/10428190601186168","article-title":"Pulsed cyclophosphamide, thalidomide and dexamethasone regimen for previously treated patients with multiple myeloma: long term follow up and disease control after subsequent treatments","volume":"48","author":"Roussou","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib52","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1365-2141.2008.07360.x","article-title":"Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed\/refractory myeloma","volume":"143","author":"Morris","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib53","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1046\/j.1365-2141.2003.04345.x","article-title":"Thalidomide and dexamethasone for resistant multiple myeloma","volume":"121","author":"Anagnostopoulos","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib54","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-0609.2005.00610.x","article-title":"Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma","volume":"76","author":"Palumbo","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib55","first-page":"399","article-title":"Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma","volume":"86","author":"Palumbo","year":"2001","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib56","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/sj.thj.6200403","article-title":"Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma","volume":"5","author":"Palumbo","year":"2004","journal-title":"Hematol J"},{"issue":"4 suppl 4","key":"10.1053\/j.seminhematol.2012.05.003_bib57","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/j.seminhematol.2003.09.006","article-title":"Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma","volume":"40","author":"Alexanian","year":"2003","journal-title":"Semin Hematol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib58","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1023\/A:1011132808904","article-title":"Thalidomide and dexamethasone combination for refractory multiple myeloma","volume":"12","author":"Dimopoulos","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib59","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1046\/j.1365-2141.2003.04473.x","article-title":"Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma","volume":"122","author":"Kropff","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib60","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/sj.thj.6200326","article-title":"Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma","volume":"5","author":"Dimopoulos","year":"2004","journal-title":"Hematol J"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib61","first-page":"862","article-title":"Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma","volume":"91","author":"Sidra","year":"2006","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib62","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00277-004-0981-5","article-title":"Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study","volume":"84","author":"Hovenga","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib63","first-page":"1432","article-title":"Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study","volume":"88","author":"Offidani","year":"2003","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib64","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1385\/MO:19:4:219","article-title":"Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma","volume":"19","author":"Srkalovic","year":"2002","journal-title":"Med Oncol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib65","first-page":"133","article-title":"Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed\/refractory multiple myeloma: a prospective, multicenter, phase II study","volume":"91","author":"Offidani","year":"2006","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib66","doi-asserted-by":"crossref","first-page":"889","DOI":"10.4065\/81.7.889","article-title":"Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma","volume":"81","author":"Hussein","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib67","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1182\/blood.V98.13.3846","article-title":"Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy","volume":"98","author":"Moehler","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib68","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0960-894X(99)00250-4","article-title":"Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production","volume":"9","author":"Muller","year":"1999","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib69","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","article-title":"Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib70","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/blood-2008-12-196238","article-title":"Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma","volume":"114","author":"Richardson","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib71","article-title":"Results of phase I study of CC-5013 for the treatment of multiple myeloma patients who relapse after high dose chemotherapy (HDCT)","author":"Zangari","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib72","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib73","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Multiple Myeloma 9010) Study Investigators","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib74","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdl313","article-title":"Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy","volume":"17","author":"Baz","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib75","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1182\/blood-2008-10-184135","article-title":"Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)","volume":"113","author":"Knop","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib76","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.1874.1874","article-title":"Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide (revlimid(R)) (CPR) for the treatment of patients with relapsed and refractory multiple myeloma","volume":"114","author":"Reece","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib77","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.3707.3707","article-title":"CRD: a phase 1 dose escalation study to determine the maximum tolerated dose of cyclophosphamide in combination with lenalidomide and dexamethasone in relapsed\/refractory myeloma","volume":"112","author":"Schey","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib78","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/leu.2009.147","article-title":"Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib79","doi-asserted-by":"crossref","DOI":"10.3109\/10428194.2011.654116","article-title":"Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma","author":"Touzeau","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib80","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib81","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-2141.2009.07931.x","article-title":"Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide\/dexamethasone-refractory myeloma","volume":"148","author":"van de Donk","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib82","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1365-2141.2007.06538.x","article-title":"Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients","volume":"137","author":"Morgan","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib83","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","article-title":"Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies","volume":"20","author":"Orlowski","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib84","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib85","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","article-title":"A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma","volume":"127","author":"Jagannath","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib86","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"; Assessment of Proteasome Inhibition for Extending Remossions (APEX) Investigators","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib87","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","article-title":"Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib88","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib89","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1365-2141.2007.06656.x","article-title":"Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma","volume":"138","author":"Kropff","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib90","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1093\/annonc\/mdn018","article-title":"Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma","volume":"19","author":"Palumbo","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib91","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1200\/JCO.2008.19.5370","article-title":"Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma","volume":"27","author":"Jakubowiak","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib92","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1200\/JCO.2005.03.2383","article-title":"Phase I\/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma","volume":"24","author":"Berenson","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib93","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1200\/JCO.2007.14.2372","article-title":"Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma","volume":"26","author":"Reece","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib94","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1365-2141.2008.07572.x","article-title":"Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma","volume":"144","author":"Popat","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib95","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.leukres.2004.11.004","article-title":"Bortezomib in combination with dexamethasone for relapsed multiple myeloma","volume":"29","author":"Kropff","year":"2005","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib96","first-page":"929","article-title":"Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and\/or refractory multiple myeloma with less than optimal response to bortezomib alone","volume":"91","author":"Jagannath","year":"2006","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib97","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2141.2008.07409.x","article-title":"High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program","volume":"144","author":"Mikhael","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib98","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3324\/haematol.11228","article-title":"The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone","volume":"92","author":"Davies","year":"2007","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib99","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1365-2141.2008.07147.x","article-title":"The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma","volume":"141","author":"Ciolli","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib100","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1038\/leu.2008.235","article-title":"The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed\/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis","volume":"22","author":"Terpos","year":"2008","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib101","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1182\/blood-2006-08-042275","article-title":"Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma","volume":"109","author":"Palumbo","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib102","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/leu.2008.99","article-title":"VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma","volume":"22","author":"Pineda-Roman","year":"2008","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib103","doi-asserted-by":"crossref","first-page":"5713","DOI":"10.1200\/JCO.2009.22.2679","article-title":"Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed\/refractory multiple myeloma","volume":"27","author":"Richardson","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib104","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.2864.2864","article-title":"A prospective randomized phase i\/ii study of lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed\/refractory multiple myeloma patients","volume":"114","author":"Cavallo","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib105","article-title":"Lenalidomide, bortezomib, and dexamethasone in patients with relapsed or relapsed\/refractory multiple myeloma (MM): encouraging response rates and tolerability with correlation of outcome and adverse cytogenetics in a phase II study","volume":"112","author":"Richardson","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib106","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.1815.1815","article-title":"The addition of bortezomib to the combination of lenalidomide and dexamethasone increases bone formation in relapsed\/refractory myeloma: a prospective study in 91 patients","volume":"114","author":"Terpos","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib107","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib108","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1600-0609.2008.01121.x","article-title":"A systematic review of phase II trials of thalidomide\/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma","volume":"81","author":"von Lilienfeld-Toal","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib109","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nrclinonc.2009.128","article-title":"Neurological adverse effects caused by cytotoxic and targeted therapies","volume":"6","author":"Schiff","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib110","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3816\/SCT.2006.n.027","article-title":"Optimizing the management of treatment-related peripheral neuropathy in patients with multiple myeloma","volume":"4","author":"Reddy","year":"2006","journal-title":"Support Cancer Ther"},{"issue":"Suppl 2","key":"10.1053\/j.seminhematol.2012.05.003_bib111","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S0305-7372(10)70009-8","article-title":"Management of treatment-related adverse events in patients with multiple myeloma","volume":"36","author":"Mateos","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib112","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.leukres.2007.12.002","article-title":"Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens","volume":"32","author":"van Marion","year":"2008","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib113","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib114","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1038\/sj.leu.2403533","article-title":"Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy","volume":"18","author":"Minnema","year":"2004","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib115","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1365-2141.2004.05078.x","article-title":"Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation","volume":"126","author":"Zangari","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib116","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1080\/10428190701647887","article-title":"Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma","volume":"48","author":"Niesvizky","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib117","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1182\/blood-2007-10-117457","article-title":"Thalidomide for treatment of multiple myeloma: 10 years later","volume":"111","author":"Palumbo","year":"2008","journal-title":"Blood"},{"author":"Summit","key":"10.1053\/j.seminhematol.2012.05.003_bib118"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib119","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1182\/blood-2011-11-374249","article-title":"IMWG consensus on maintenance therapy in multiple myeloma","volume":"119","author":"Ludwig","year":"2012","journal-title":"Blood"},{"issue":"suppl","key":"10.1053\/j.seminhematol.2012.05.003_bib120","article-title":"Lenalidomide and dexamethasone (LEN plus DEX) treatment in relapsed\/refractory multiple myeloma (RRMM) patients (pts) and risk of second primary malignancies (SPM): Analysis of MM-009\/010","volume":"29","author":"Dimopoulos","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib121","first-page":"1","article-title":"Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma","volume":"4","author":"Richardson","year":"2006","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib122","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1007\/s12032-009-9262-4","article-title":"Multiple myeloma: management of adverse events","volume":"27","author":"Gay","year":"2010","journal-title":"Med Oncol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib123","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.leukres.2009.07.022","article-title":"Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients","volume":"34","author":"Corso","year":"2010","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib124","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1200\/JCO.2008.18.3087","article-title":"Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy","volume":"27","author":"Richardson","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib125","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","article-title":"Efficacy and safety of once-weekly bortezomib in multiple myeloma patients","volume":"116","author":"Bringhen","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib126","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib127","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1200\/JCO.2007.14.9641","article-title":"Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib128","unstructured":"Altekruse S, Kosary C, Krapcho M, et al (eds). SEER Cancer Statistics Review 1975\u20132007. National Cancer Institute. Bethesda, MD, http:\/\/seer.cancer.gov\/csr\/1975-2007\/. Based on November 2009 SEER data submission posted to the SEER Website, 2010. Accessed on March 19, 2012."},{"key":"10.1053\/j.seminhematol.2012.05.003_bib129","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2011-06-358812","article-title":"Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)","volume":"118","author":"Palumbo","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib130","first-page":"1","article-title":"Cancer pain relief and palliative care","volume":"804","year":"1990","journal-title":"World Health Organ Tech Rep Ser"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib131","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/0360-3016(93)90308-I","article-title":"Radiation therapy for the palliation of multiple myeloma","volume":"25","author":"Leigh","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib132","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events","volume":"16","author":"Berenson","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib133","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma","volume":"334","author":"Berenson","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib134","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib135","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(11)70157-7","article-title":"Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial","volume":"12","author":"Morgan","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib136","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/annonc\/mdn796","article-title":"The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network","volume":"20","author":"Terpos","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib137","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1445-5994.2008.01824.x","article-title":"Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment","volume":"39","author":"Dickinson","year":"2009","journal-title":"Intern Med J"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib138","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/leu.2008.131","article-title":"Pathogenesis and treatment of renal failure in multiple myeloma","volume":"22","author":"Dimopoulos","year":"2008","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib139","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1056\/NEJMcp042806","article-title":"Clinical practice","volume":"352","author":"Stewart","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib140","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1200\/JCO.2007.14.3396","article-title":"Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology\/American Society of Hematology clinical practice guideline update","volume":"26","author":"Rizzo","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib141","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.6004\/jnccn.2011.0098","article-title":"Management of relapsed and relapsed\/refractory multiple myeloma","volume":"9","author":"Laubach","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib142","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1200\/JCO.2007.13.8545","article-title":"Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome","volume":"26","author":"Decaux","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib143","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/sj.leu.2404442","article-title":"Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials","volume":"21","author":"Jagannath","year":"2007","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib144","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib145","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1200\/JCO.2010.28.3945","article-title":"Bortezomib plus dexamethasone induction improves outcome in patients with t(4;14) myeloma but not outcome of patients with del(17p)","volume":"28","author":"Avet-Loiseau","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib146","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1182\/blood-2011-09-379164","article-title":"Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p","volume":"119","author":"Neben","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib147","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1600-0609.1994.tb00190.x","article-title":"Renal function in newly diagnosed multiple myeloma\u2014a demographic study of 1353 patients","volume":"53","author":"Knudsen","year":"1994","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib148","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/cncr.20888","article-title":"Bortezomib in recurrent and\/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function","volume":"103","author":"Jagannath","year":"2005","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib149","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/sj.leu.2405087","article-title":"Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study","volume":"22","author":"San-Miguel","year":"2008","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib150","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1600-0609.2004.00272.x","article-title":"Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure","volume":"73","author":"Tosi","year":"2004","journal-title":"Eur J Haematol"},{"year":"2006","key":"10.1053\/j.seminhematol.2012.05.003_bib151"},{"year":"2011","key":"10.1053\/j.seminhematol.2012.05.003_bib152"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib153","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","article-title":"Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib","volume":"24","author":"Richardson","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.05.003_bib154","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1634\/theoncologist.2009-0203","article-title":"Current multiple myeloma treatment strategies with novel agents: a European perspective","volume":"15","author":"Ludwig","year":"2010","journal-title":"Oncologist"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196312000376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196312000376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:21:55Z","timestamp":1758522115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196312000376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":154,"alternative-id":["S0037196312000376"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2012.05.003","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2012,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management Strategies for Relapsed\/Refractory Multiple Myeloma: Current Clinical Perspectives","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2012.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}